Autologous Transplantation
Autologous Transplantation - Related Videos
08:58
Matrix-assisted Autologous Chondrocyte Transplantation for Remodeling and Repair of Chondral Defects in a Rabbit Model
0 Views •
Cited by 5 •
2013
An experimental technique for the treatment of chondral defects in the rabbit's knee joint is described. The implantation of autologous chondrocytes seeded on a matrix is a well-accepted method for the remodeling and repair of articular cartilage lesions providing satisfying long-term results. Matrix-assisted autologous chondrocyte transplantation (MACT) offers a standardized and clinically established implantation method.
10:15
Steps for the Autologous Ex vivo Perfused Porcine Liver-kidney Experiment
0 Views •
Cited by 2 •
2013
Study of the animal organ physiology can be achieved by performing an experimental ex vivo perfusion system. The addition of a porcine kidney, as a homeostatic organ to our previously developed ex vivo liver perfusion model can be a principal step to achieve a better physiological environment.
08:15
Cervical Heterotopic Mouse Heart Transplantation using End-to-side Anastomosis Technique to Study Transplant Immunology
0 Views •
2026
This protocol presents a simplified, end-to-side suture anastomosis technique for murine cervical heart transplantation, providing a robust and reproducible model for studying transplant immunology.
10:44
Modeling Intracerebral Hemorrhage in Mice: Injection of Autologous Blood or Bacterial Collagenase
0 Views •
Cited by 60 •
2012
Clinically relevant animal models of intracerebral hemorrhage (ICH) are needed to extend our knowledge of hemorrhagic stroke and to examine novel therapeutic strategies. In this study, we describe and evaluate two ICH models that implement unilateral injections of either autologous whole blood or bacterial collagenase into the basal ganglia (corpus striatum) of mice.
09:54
Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
0 Views •
Cited by 8 •
2018
This protocol is intended to describe porcine hepatocyte isolation and ex vivo gene delivery to cure models of metabolic diseases via autologous cell transplantation. Although this particular model enjoys unique advantages that favor successful therapy, the application is a relevant foundation to address additional diseases and indications.
FAQs
Its central biological advantage is compatibility between the collected material and the recipient. Because the cells, tissue, or organ originated in that same individual, the procedure avoids many problems associated with donor-recipient incompatibility. This makes immune acceptance a major reason for selecting an autologous approach when suitable patient-derived material can be obtained and preserved.
After intensive treatment, reinfused hematopoietic stem cells can repopulate the bone marrow, the tissue responsible for producing blood cells. Their return supports restoration of blood-cell production after treatment has affected the patient’s blood-forming system. The biological outcome therefore depends not only on reinfusion, but also on whether the harvested cells remain suitable for this rebuilding process.
Success depends strongly on the quality of the collected material and the condition of the patient’s tissue or disease. In hematopoietic transplantation, the harvested blood-forming stem cells must be suitable for later reinfusion and marrow repopulation. These factors help determine whether the transplanted material can perform its intended restorative role after intensive treatment.
The procedure begins by collecting the patient’s blood-forming stem cells, followed by storage when needed. The patient then receives intensive treatment, after which the preserved cells are reinfused. Those cells subsequently repopulate the bone marrow and support renewed blood-cell production. This sequence separates cell collection from treatment and allows the patient’s own material to be returned afterward.
The approach has uses in cancer treatment, tissue repair, and regenerative medicine. In cancer-related care, collected hematopoietic stem cells can be returned after intensive treatment to help restore blood formation. In tissue repair and regenerative applications, patient-derived material can support restoration while avoiding many complications linked to donor-recipient incompatibility.
This procedure demonstrates how biological compatibility and tissue-specific function shape therapeutic outcomes. A patient’s own material can be collected, preserved, and returned for a defined role, such as rebuilding bone-marrow blood production. It also connects cellular biology with regenerative medicine by showing how transplanted cells may contribute to tissue restoration when the patient’s condition permits.